Corcept (CORT) Q4 Earnings: What To Expect

Corcept (CORT) Q4 Earnings: What To Expect

Radek Strnad

Mon, February 23, 2026 at 12:12 PM GMT+9 2 min read

In this article:

CORT

+1.69%

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

Corcept missed analysts’ revenue expectations last quarter, reporting revenues of $207.6 million, up 13.7% year on year. It was a softer quarter for the company, with full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ revenue estimates.

Is Corcept a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Corcept’s revenue to grow 36.3% year on year, improving from the 34.3% increase it recorded in the same quarter last year.

Corcept Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Corcept has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Corcept’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 42.6%, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported revenues up 1.4%, topping estimates by 4.8%. Eli Lilly traded up 1.7% following the results while Bristol-Myers Squibb was also up 7.6%.

Read our full analysis of Eli Lilly’s results here and Bristol-Myers Squibb’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Corcept is down 23.3% during the same time and is heading into earnings with an average analyst price target of $76.40 (compared to the current share price of $34.94).

P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.

Terms and Privacy Policy

Privacy Dashboard

More Info